Telaprevir: pharmacokinetics and drug interactions.
Article Details
- CitationCopy to clipboard
Garg V, Kauffman RS, Beaumont M, van Heeswijk RP
Telaprevir: pharmacokinetics and drug interactions.
Antivir Ther. 2012;17(7):1211-21. doi: 10.3851/IMP2356. Epub 2012 Sep 7.
- PubMed ID
- 22954756 [ View in PubMed]
- Abstract
Telaprevir is an inhibitor of the HCV NS3/4A protease. When used in combination with pegylated interferon and ribavirin, telaprevir has demonstrated a substantial increase in sustained virological response compared with pegylated interferon and ribavirin used alone. Telaprevir has good oral bioavailability, which is enhanced when administered with food. Telaprevir is extensively metabolized and primarily eliminated via faeces. No dose adjustment of telaprevir is needed in patients with mild to severe renal impairment or mild liver impairment. Telaprevir is a substrate and inhibitor of cytochrome P450 3A and P-glycoprotein and, thus, might interact with coadministered drugs that affect or are affected by these metabolic/transport pathways. This article reviews the pharmacokinetic and drug interaction profile of telaprevir.
DrugBank Data that Cites this Article
- Drugs
- Drug Carriers
Drug Carrier Kind Organism Pharmacological Action Actions Telaprevir Alpha-1-acid glycoprotein 1 Protein Humans NoSubstrateDetails Telaprevir Serum albumin Protein Humans NoSubstrateDetails - Drug Interactions
Drugs Interaction Integrate drug-drug
interactions in your softwareTelaprevirAmprenavir The serum concentration of Telaprevir can be decreased when it is combined with Amprenavir. TelaprevirFosamprenavir The serum concentration of Telaprevir can be decreased when it is combined with Fosamprenavir. ZolpidemTelaprevir The serum concentration of Zolpidem can be decreased when it is combined with Telaprevir.